Close Menu
World Economist – Global Markets, Finance & Economic Insights
  • Home
  • Economist Impact
    • Economist Intelligence
    • Finance & Economics
  • Business
  • Asia
  • China
  • Europe
  • Economy
  • USA
    • Middle East & Africa
    • Highlights
  • This week
  • World Economy
    • World News
What's Hot

Calcorp to fully acquire solar venture Helios Resol Technology – Business & Finance

September 5, 2025

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

September 5, 2025

Starbucks China valued at about US$5 billion by bidders, sources say

September 5, 2025
Facebook X (Twitter) Instagram
Friday, September 5
Facebook X (Twitter) Instagram
World Economist – Global Markets, Finance & Economic Insights
  • Home
  • Economist Impact
    • Economist Intelligence
    • Finance & Economics
  • Business
  • Asia
  • China
  • Europe
  • Economy
  • USA
    • Middle East & Africa
    • Highlights
  • This week
  • World Economy
    • World News
World Economist – Global Markets, Finance & Economic Insights
Home » Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly
USA

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

adminBy adminJuly 1, 2007No Comments2 Mins Read
Share Facebook Twitter Pinterest Copy Link LinkedIn Tumblr Email VKontakte Telegram
Share
Facebook Twitter Pinterest Email Copy Link
Post Views: 82


Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance.

Danish drugmaker Novo Nordisk (NVO) said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of $499, down from $650, takes effect immediately.

Novo said the new pricing is available to both the uninsured and people who have insurance that doesn’t cover the weight-loss drugs.

Last week, Eli Lilly (LLY) said it would cut the monthly price of its starter dose of Zepbound to $349. The U.S. drugmaker also is making larger doses available for $499 through its self-pay program.

NYSE – Delayed Quote • USD

LLY NVO

Patients start taking the injectable drugs at smaller dose levels and then increase the amount over time.

The price cuts come as supplies improve. The U.S. Food and Drug Administration has moved both drugs off its list of medicines in shortage. The agency has said compounding pharmacies and other entities that have been allowed to make off-brand, cheaper copies of the drugs during the shortage will have to wind down production.

Wegovy and Zepbound are part of a GLP-1 class of treatments that has shown unprecedented results for helping people shed weight by decreasing appetite and boosting feelings of fullness. Sales of the drugs have soared.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Telegram Copy Link
admin
  • Website

Related Posts

USA

Why Intel investors have embraced an interventionist White House

August 28, 2025
USA

Trump’s attack on the Fed threatens US credibility

August 27, 2025
USA

The next stage of the Fed takeover

August 27, 2025
USA

Surging US electricity prices put Trump pledge in jeopardy

August 27, 2025
USA

EU moves to shield aluminium from Trump tariff blow

August 27, 2025
USA

Donald Trump’s battle against the Fed heads for courtroom showdown

August 26, 2025
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Calcorp to fully acquire solar venture Helios Resol Technology – Business & Finance

September 5, 2025

SECP alerts public against Ponzi scheme – Business & Finance

September 5, 2025

Green channel: Facility to compliant traders may be extended – Business & Finance

September 5, 2025

‘Eighteen’ housing society announces its new CEO – Business & Finance

September 5, 2025
Latest Posts

PSX hits all-time high as proposed ‘neutral-to-positive’ budget well-received by investors – Business

June 11, 2025

Sindh govt to allocate funds for EV taxis, scooters in provincial budget: minister – Pakistan

June 11, 2025

US, China reach deal to ease export curbs, keep tariff truce alive – World

June 11, 2025

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Recent Posts

  • Calcorp to fully acquire solar venture Helios Resol Technology – Business & Finance
  • China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug
  • Starbucks China valued at about US$5 billion by bidders, sources say
  • China’s Victory Day parade, US TV series draws flak in Singapore: SCMP’s 7 highlights
  • Thailand’s Thaksin flies to Dubai after missing Singapore airport landing deadline

Recent Comments

No comments to show.

Welcome to World-Economist.com, your trusted source for in-depth analysis, expert insights, and the latest news on global finance and economics. Our mission is to provide readers with accurate, data-driven reports that shape the understanding of economic trends worldwide.

Latest Posts

Calcorp to fully acquire solar venture Helios Resol Technology – Business & Finance

September 5, 2025

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

September 5, 2025

Starbucks China valued at about US$5 billion by bidders, sources say

September 5, 2025

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Archives

  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • June 2024
  • October 2022
  • March 2022
  • July 2021
  • February 2021
  • January 2021
  • November 2019
  • April 2011
  • January 2011
  • December 2007
  • July 2007

Categories

  • AI & Tech
  • Asia
  • Banking
  • Business
  • Business
  • China
  • Climate
  • Computing
  • Economist Impact
  • Economist Intelligence
  • Economy
  • Editor's Choice
  • Europe
  • Europe
  • Featured
  • Featured Business
  • Featured Climate
  • Featured Health
  • Featured Science & Tech
  • Featured Travel
  • Finance & Economics
  • Health
  • Highlights
  • Markets
  • Middle East
  • Middle East & Africa
  • Middle East News
  • Most Viewed News
  • News Highlights
  • Other News
  • Politics
  • Russia
  • Science
  • Science & Tech
  • Social
  • Space Science
  • Sports
  • Sports Roundup
  • Tech
  • This week
  • Top Featured
  • Travel
  • Trending Posts
  • Ukraine Conflict
  • Uncategorized
  • US Politics
  • USA
  • World
  • World & Politics
  • World Economy
  • World News
© 2025 world-economist. Designed by world-economist.
  • Home
  • About Us
  • Advertise With Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.